Tong Ren Tang Sinopharm (3613.HK): Mainland China sales restart and are expected to resume strong growth in 2024
Damo: Maintaining Tong Ren Tang Sinopharm's (03613) “Gain” Rating and Lowering the Target Price to HK$15
Tong Ren Tang Sinopharm (3613.HK): The mainland market is under short-term pressure and is optimistic about a steady recovery in 24 years
Tong Ren Tang Sinopharm (03613.HK): 2023 results are in line with expectations, gross margin increased year-on-year
Tong Ren Tang Sinopharm (03613.HK): The Hong Kong market will maintain a positive recovery trend in 2023, and Ganoderma lucidum spore powder is expected to resume growth in 2024
Damo: Lowering the target price of Tong Ren Tang Sinopharm (03613) by 7% to HK$17 rating “increase”
Tong Ren Tang Chinese Medicine (03613.HK): The company has recovered from the epidemic and has ushered in high revenue and profit growth
Tong Ren Tang Chinese Medicine (3613.HK): The core region achieved rapid recovery, H1 performance in '23 was in line with expectations
First Shanghai: Maintaining Tongrentang Pharmaceutical's (03613) “Buy” Rating Target Price at HK$19.7
Changes in Hong Kong stocks | Tongrentang Sinopharm rose nearly 5% to raise target price to HK$16
Big Bank Ratings | Daimo: Raising the target price of Tongrentang Chinese Medicine (3613.HK) to HK$16
CICC: Maintains Tongrentang Sinopharm's (03613) “Outperform Industry” rating and rises to HK$15.11
Daima: Give Tongrentang Sinopharm (03613) a target price of HK$14.2 for the “increase in holdings” rating
Daima: Give Tongrentang Sinopharm (03613) a target price of HK$14.2 for the “increase in holdings” rating
Tongrentang Sinopharm (3613.HK): Interim results are under pressure in the short term, and H2 is expected to gradually recover
Tongrentang Sinopharm (03613.HK): The results for the first half of the year were in line with expectations and actively expanded new channels
Tongrentang Sinopharm (03613.HK): 2021 revenue slightly exceeds expectations, net profit is in line with expectations
Tongrentang Sinopharm (03613.HK): Results for the first half of 2021 are in line with expectations, actively developing e-commerce business
Tong Ren Tang Chinese Medicine (3613.HK): The worst period has passed and the business situation is gradually recovering
Tong Ren Tang Chinese Medicine (03613.HK): Performance exceeds expectations and the Hong Kong market is expected to gradually recover
No Data